- Home
- BIRK vs ROIV Comparison
BIRK vs ROIV Comparison
Compare BIRK & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRK
- ROIV
- Stock Information
- Founded
- BIRK 1774
- ROIV 2014
- Country
- BIRK United Kingdom
- ROIV United Kingdom
- Employees
- BIRK N/A
- ROIV N/A
- Industry
- BIRK
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- BIRK
- ROIV Health Care
- Exchange
- BIRK Nasdaq
- ROIV Nasdaq
- Market Cap
- BIRK 8.9B
- ROIV 8.4B
- IPO Year
- BIRK 2023
- ROIV N/A
- Fundamental
- Price
- BIRK $47.82
- ROIV $11.97
- Analyst Decision
- BIRK Buy
- ROIV Strong Buy
- Analyst Count
- BIRK 19
- ROIV 10
- Target Price
- BIRK $60.83
- ROIV $17.39
- AVG Volume (30 Days)
- BIRK 1.9M
- ROIV 6.2M
- Earning Date
- BIRK 08-29-2024
- ROIV 11-11-2024
- Dividend Yield
- BIRK N/A
- ROIV N/A
- EPS Growth
- BIRK N/A
- ROIV N/A
- EPS
- BIRK 0.63
- ROIV 5.65
- Revenue
- BIRK $1,846,639,880.00
- ROIV $158,303,000.00
- Revenue This Year
- BIRK $22.73
- ROIV $45.51
- Revenue Next Year
- BIRK $17.26
- ROIV $37.40
- P/E Ratio
- BIRK $75.92
- ROIV $2.12
- Revenue Growth
- BIRK 19.77
- ROIV 101.44
- 52 Week Low
- BIRK $35.83
- ROIV $8.25
- 52 Week High
- BIRK $64.78
- ROIV $13.24
- Technical
- Relative Strength Index (RSI)
- BIRK 37.82
- ROIV 53.23
- Support Level
- BIRK $42.91
- ROIV $11.78
- Resistance Level
- BIRK $49.33
- ROIV $12.38
- Average True Range (ATR)
- BIRK 1.68
- ROIV 0.43
- MACD
- BIRK 0.19
- ROIV -0.06
- Stochastic Oscillator
- BIRK 66.62
- ROIV 29.90
About BIRK Birkenstock Holding plc
Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. The company operates in four operating segments based on its regional hubs: Americas, Europe and APMA (Asia Pacific, Middle East and Africa). The company sells its products through two main channels: business-to-business (B2B) and direct-to-consumer (DTC).
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.